Impact of BCR::ABL1 transcript type on RT-qPCR amplification
performance and molecular response to therapy

J 2022

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

SALMON, M., H. E. WHITE, Hana ZIZKOVA, A. GOTTSCHALK, Eliska MOTLOVA et. al.

Základní údaje

Originální název

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

Autoři

SALMON, M., H. E. WHITE, Hana ZIZKOVA (203 Česká republika), A. GOTTSCHALK, Eliska MOTLOVA (203 Česká republika), N. CERVEIRA, D. COLOMER, D. CORIU, G. N. FRANKE, E. GOTTARDI, B. IZZO, Tomáš JURČEK (203 Česká republika, domácí), T. LION, V. SCHAFER, C. VENTURI, P. VIGNERI, M. ZAWADA, Jan ZUNA (203 Česká republika), Lenka HOVORKOVA (203 Česká republika), Jitka KOBLIHOVA (203 Česká republika), Hana KLAMOVA (203 Česká republika), Marketa MARKOVA STASTNA (203 Česká republika), Dana SRBOVA (203 Česká republika), Adela BENESOVA (203 Česká republika), Vaclava POLIVKOVA, Daniela ŽÁČKOVÁ (203 Česká republika, domácí), Jiří MAYER (203 Česká republika, domácí), I. ROEDER, I. GLAUCHE, T. ERNST, A. HOCHHAUS, K. M. POLAKOVA a N. C. P. CROSS (garant)

Vydání

Leukemia, LONDON, Springer, 2022, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.400

Kód RIV

RIV/00216224:14110/22:00126254

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/s41375-022-01612-2

UT WoS

000807908400001

Klíčová slova anglicky

Cancer genetics; Myeloproliferative disease

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 7. 2022 09:25, Mgr. Tereza Miškechová

Anotace

V originále

Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::ABL1 have a faster molecular response to therapy compared to patients expressing e13a2. To explore the reason for this difference we undertook a detailed technical comparison of the commonly used Europe Against Cancer (EAC) BCR::ABL1 reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) assay in European Treatment and Outcome Study (EUTOS) reference laboratories (n = 10). We found the amplification ratio of the e13a2 amplicon was 38% greater than e14a2 (p = 0.015), and the amplification efficiency was 2% greater (P = 0.17). This subtle difference led to measurable transcript-type dependent variation in estimates of residual disease which could be corrected by (i) taking the qPCR amplification efficiency into account, (ii) using alternative RT-qPCR approaches or (iii) droplet digital PCR (ddPCR), a technique which is relatively insensitive to differences in amplification kinetics. In CML patients, higher levels of BCR::ABL1/GUSB were identified at diagnosis for patients expressing e13a2 (n = 67) compared to e14a2 (n = 78) when analysed by RT-qPCR (P = 0.0005) but not ddPCR (P = 0.5). These data indicate that widely used RT-qPCR assays result in subtly different estimates of disease depending on BCR::ABL1 transcript type; these differences are small but may need to be considered for optimal patient management.

Citovat

SALMON, M., H. E. WHITE, Hana ZIZKOVA, A. GOTTSCHALK, Eliska MOTLOVA, N. CERVEIRA, D. COLOMER, D. CORIU, G. N. FRANKE, E. GOTTARDI, B. IZZO, Tomáš JURČEK, T. LION, V. SCHAFER, C. VENTURI, P. VIGNERI, M. ZAWADA, Jan ZUNA, Lenka HOVORKOVA, Jitka KOBLIHOVA, Hana KLAMOVA, Marketa MARKOVA STASTNA, Dana SRBOVA, Adela BENESOVA, Vaclava POLIVKOVA, Daniela ŽÁČKOVÁ, Jiří MAYER, I. ROEDER, I. GLAUCHE, T. ERNST, A. HOCHHAUS, K. M. POLAKOVA a N. C. P. CROSS. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia. LONDON: Springer, 2022, roč. 36, č. 7, s. 1879-1886. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-022-01612-2.

@article{1874629,
   author = {Salmon, M. and White, H. E. and Zizkova, Hana and Gottschalk, A. and Motlova, Eliska and Cerveira, N. and Colomer, D. and Coriu, D. and Franke, G. N. and Gottardi, E. and Izzo, B. and Jurček, Tomáš and Lion, T. and Schafer, V. and Venturi, C. and Vigneri, P. and Zawada, M. and Zuna, Jan and Hovorkova, Lenka and Koblihova, Jitka and Klamova, Hana and Markova Stastna, Marketa and Srbova, Dana and Benesova, Adela and Polivkova, Vaclava and Žáčková, Daniela and Mayer, Jiří and Roeder, I. and Glauche, I. and Ernst, T. and Hochhaus, A. and Polakova, K. M. and Cross, N. C. P.},
   article_location = {LONDON},
   article_number = {7},
   doi = {http://dx.doi.org/10.1038/s41375-022-01612-2},
   keywords = {Cancer genetics; Myeloproliferative disease},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy},
   url = {https://www.nature.com/articles/s41375-022-01612-2},
   volume = {36},
   year = {2022}
}

TY  - JOUR
ID  - 1874629
AU  - Salmon, M. - White, H. E. - Zizkova, Hana - Gottschalk, A. - Motlova, Eliska - Cerveira, N. - Colomer, D. - Coriu, D. - Franke, G. N. - Gottardi, E. - Izzo, B. - Jurček, Tomáš - Lion, T. - Schafer, V. - Venturi, C. - Vigneri, P. - Zawada, M. - Zuna, Jan - Hovorkova, Lenka - Koblihova, Jitka - Klamova, Hana - Markova Stastna, Marketa - Srbova, Dana - Benesova, Adela - Polivkova, Vaclava - Žáčková, Daniela - Mayer, Jiří - Roeder, I. - Glauche, I. - Ernst, T. - Hochhaus, A. - Polakova, K. M. - Cross, N. C. P.
PY  - 2022
TI  - Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
JF  - Leukemia
VL  - 36
IS  - 7
SP  - 1879-1886
EP  - 1879-1886
PB  - Springer
SN  - 08876924
KW  - Cancer genetics
KW  - Myeloproliferative disease
UR  - https://www.nature.com/articles/s41375-022-01612-2
N2  - Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::ABL1 have a faster molecular response to therapy compared to patients expressing e13a2. To explore the reason for this difference we undertook a detailed technical comparison of the commonly used Europe Against Cancer (EAC) BCR::ABL1 reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) assay in European Treatment and Outcome Study (EUTOS) reference laboratories (n = 10). We found the amplification ratio of the e13a2 amplicon was 38% greater than e14a2 (p = 0.015), and the amplification efficiency was 2% greater (P = 0.17). This subtle difference led to measurable transcript-type dependent variation in estimates of residual disease which could be corrected by (i) taking the qPCR amplification efficiency into account, (ii) using alternative RT-qPCR approaches or (iii) droplet digital PCR (ddPCR), a technique which is relatively insensitive to differences in amplification kinetics. In CML patients, higher levels of BCR::ABL1/GUSB were identified at diagnosis for patients expressing e13a2 (n = 67) compared to e14a2 (n = 78) when analysed by RT-qPCR (P = 0.0005) but not ddPCR (P = 0.5). These data indicate that widely used RT-qPCR assays result in subtly different estimates of disease depending on BCR::ABL1 transcript type; these differences are small but may need to be considered for optimal patient management.
ER  -

SALMON, M., H. E. WHITE, Hana ZIZKOVA, A. GOTTSCHALK, Eliska MOTLOVA, N. CERVEIRA, D. COLOMER, D. CORIU, G. N. FRANKE, E. GOTTARDI, B. IZZO, Tomáš JURČEK, T. LION, V. SCHAFER, C. VENTURI, P. VIGNERI, M. ZAWADA, Jan ZUNA, Lenka HOVORKOVA, Jitka KOBLIHOVA, Hana KLAMOVA, Marketa MARKOVA STASTNA, Dana SRBOVA, Adela BENESOVA, Vaclava POLIVKOVA, Daniela ŽÁČKOVÁ, Jiří MAYER, I. ROEDER, I. GLAUCHE, T. ERNST, A. HOCHHAUS, K. M. POLAKOVA a N. C. P. CROSS. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. \textit{Leukemia}. LONDON: Springer, 2022, roč.~36, č.~7, s.~1879-1886. ISSN~0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-022-01612-2.

Podrobný výpis o publikaci